Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Physiomics ( (GB:PYC) ) has provided an announcement.
Physiomics plc announced a 46% increase in total income for the financial year ending June 2025, alongside a 32% reduction in operating loss, signaling strong financial health and operational efficiency. The company has expanded its service offerings by launching a Biometrics service line and diversifying into new therapeutic areas, with significant contract wins and a growing client base, indicating robust industry positioning and potential for future growth.
Spark’s Take on GB:PYC Stock
According to Spark, TipRanks’ AI Analyst, GB:PYC is a Underperform.
Physiomics’ stock score is primarily impacted by significant financial instability, including declining revenues and negative profit margins. Technical indicators reinforce a bearish outlook. While recent corporate events suggest potential growth pathways, current valuation issues and financial challenges remain significant obstacles.
To see Spark’s full report on GB:PYC stock, click here.
More about Physiomics
Physiomics plc is a leading company in mathematical modelling, data science, and biostatistics, focusing on developing new therapeutics and personalized medicine solutions. The company combines expertise in Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics to aid biotech and pharma companies in streamlining drug development. Their approach involves deriving insights from diverse data to optimize research design across discovery, pre-clinical, and clinical studies, using cutting-edge computational tools and proprietary Virtual Tumour technology.
Average Trading Volume: 3,201,376
Technical Sentiment Signal: Sell
Current Market Cap: £1.46M
Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.